EMA Authorised: Mavenclad (cladribine) — Merck Europe B.V.

View source ↗

Summary

The EMA authorised Mavenclad (cladribine) from Merck Europe B.V. for multiple sclerosis, marking regulatory approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Merck Europe B.V.. Decision date: 10/01/2026